Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stock Has Average Price Target of $20.11 According to Brokerages

Key Points

• Analysts maintain a Moderate Buy consensus on Phathom Pharmaceuticals, with 8 buy ratings, 1 strong buy, 1 hold and 1 sell; the average 12-month price target is $20.11.
• Third-quarter revenue rose 71% year over year to $84.7 million, driven by VOQUEZNA demand, while management reaffirmed 2026 revenue guidance of $310 million to $325 million.
• Despite the commercial growth, shares opened at $5.74—down 7.7%—and revenue slightly missed estimates; institutional investors remain heavily involved, owning approximately 99% of the stock.

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eleven research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $20.11.

Several analysts have issued reports on the stock. Guggenheim cut their price target on shares of Phathom Pharmaceuticals from $25.00 to $22.00 and set a "buy" rating for the company in a research report on Friday, July 31st. Citigroup reiterated a "buy" rating on shares of Phathom Pharmaceuticals in a report on Friday. HC Wainwright restated a "buy" rating on shares of Phathom Pharmaceuticals in a report on Friday. Weiss Ratings restated a "sell (d-)" rating on shares of Phathom Pharmaceuticals in a research report on Thursday, October 15th. Finally, Needham & Company LLC decreased their price target on Phathom Pharmaceuticals from $28.00 to $22.00 and set a "buy" rating on the stock in a research note on Thursday, July 30th.

Key Stories Impacting Phathom Pharmaceuticals

Here are the key news stories impacting Phathom Pharmaceuticals this week:

• Positive Sentiment: Q3 net revenue rose 71% year over year to $84.7 million, driven by continued demand for VOQUEZNA. The company also reported more than 2 million total VOQUEZNA prescriptions filled through October 16, 2026. Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Management reaffirmed full-year 2026 revenue guidance of $310 million to $325 million, signaling confidence in the product’s commercial trajectory. Phathom Pharmaceuticals Q3 Revenue Jumps 71%; Reaffirms FY26 Outlook
• Positive Sentiment: The planned $0 co-pay program through BlinkRx could improve patient access and support prescription volume, although its effect on net pricing and margins will be watched. Phathom Reiterates 2026 Revenue Guidance While Rolling Out $0 Co-Pay
• Neutral Sentiment: Phathom reported quarterly earnings of $0.04 per share. Results compared favorably with the year-earlier loss, but analyst assessments were mixed: one report characterized EPS as below its $0.07 consensus estimate, while another cited a consensus loss of $0.11. Phathom Q3 Earnings and Revenue Estimates
• Negative Sentiment: Revenue of $84.7 million was slightly below the approximately $84.8 million analyst estimate, while maintaining rather than raising guidance may have disappointed investors seeking further upside. Phathom Pharmaceuticals Reports Third-Quarter Results

Phathom Pharmaceuticals Stock Down 7.7%

Shares of NASDAQ:PHAT opened at $5.74 on Friday. The stock has a market cap of $464.37 million, a PE ratio of -5.57 and a beta of 0.50. The company's fifty day moving average is $7.64 and its 200 day moving average is $10.47. Phathom Pharmaceuticals has a 52 week low of $5.01 and a 52 week high of $18.31.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Catalys Pacific LLC boosted its holdings in Phathom Pharmaceuticals by 26.0% in the third quarter. Catalys Pacific LLC now owns 1,882,039 shares of the company's stock valued at $13,739,000 after acquiring an additional 388,185 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Phathom Pharmaceuticals in the 3rd quarter worth $30,000. Profund Advisors LLC lifted its position in shares of Phathom Pharmaceuticals by 602.3% in the 3rd quarter. Profund Advisors LLC now owns 121,331 shares of the company's stock worth $886,000 after purchasing an additional 104,054 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of Phathom Pharmaceuticals by 16.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,761 shares of the company's stock valued at $109,000 after purchasing an additional 2,068 shares in the last quarter. Finally, State of Alaska Department of Revenue bought a new stake in shares of Phathom Pharmaceuticals during the 3rd quarter valued at about $25,000. Institutional investors own 99.01% of the company's stock.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc NASDAQ: PHAT is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. The company's principal product is Voquezna (vonoprazan), a potassium-competitive acid blocker designed to suppress stomach acid through a mechanism distinct from traditional proton pump inhibitors.

In the United States, Voquezna is approved for the treatment of Helicobacter pylori infection in combination with antibiotics and for certain forms of gastroesophageal reflux disease (GERD), including erosive esophagitis and heartburn associated with non-erosive GERD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.